Indivior
Corporate brand
UnclaimedIndivior is a specialty pharmaceutical company focused on evidence-based treatment for opioid use disorder (OUD).
Last updated September 15, 2026
AI crawler reads
No AI crawler has read this profile yet.
Overview
Indivior is a specialty pharmaceutical company singularly focused on delivering evidence-based treatment and advancing understanding of opioid use disorder (OUD) as a chronic but treatable brain disease. It traces its origins to 1994, when Reckitt Benckiser Group PLC (RB) established the Buprenorphine Business Group, and became an independent company, Indivior PLC, following a demerger from RB in September 2014, listing on the London Stock Exchange. Its prescription medicines include SUBLOCADE (buprenorphine extended-release) injection and SUBOXONE (buprenorphine and naloxone) sublingual film, with product availability varying between countries.
History
Indivior traces its journey back more than 25 years. In 1994, Reckitt Benckiser Group PLC (RB) established the Buprenorphine Business Group. Following the demerger from RB in September 2014, Indivior PLC was established as an independent company and listed on the London Stock Exchange. The company states that it played a leading role in advancing the recognition of opioid use disorder as a medical brain disease and in bringing science-driven treatment within reach, expanding access beyond traditional settings.
Products and positioning
A specialty pharmaceutical company singularly focused on opioid use disorder, guided by science, compassion, and purpose.
SUBLOCADE (buprenorphine extended-release) injection for subcutaneous use (CIII)
SUBOXONE (buprenorphine and naloxone) Sublingual Film (CIII)
Recent events
Reported
Addex and Indivior extend GABAB PAM collaboration[5]
Addex Therapeutics reported that its strategic collaboration with Indivior on GABAB PAM had been extended with an additional $4 million in funding.
Reported
AELIS FARMA and INDIVIOR announce collaboration and option-license agreement[6]
AELIS FARMA announced a strategic collaboration and option-license agreement with INDIVIOR for AEF0117, a drug candidate for cannabis-related disorders. INDIVIOR was granted an option for an exclusive worldwide license; AELIS will conduct development during the option period.
Reported
Indivior launches Keep Moving Towards Recovery campaign[7]
Indivior announced the launch of its Keep Moving Towards Recovery direct-to-consumer advertising campaign to raise awareness of treatment with SUBLOCADE and encourage people affected by opioid use disorder and those who care about them to seek help from health care professionals.
Sources7 sources
Cite this profile: Cite the canonical profile. /brand-wiki/indivior · Editorial policy · How profiles are compiled